Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.

Taiwan: A new large-scale cohort study published in JAMA Ophthalmology has revealed that children with early-onset atopic dermatitis (AD) may be at a significantly higher risk of developing pediatric ...

The goals of treating atopic dermatitis in all patients are to restore the function of the skin barrier and to prevent and control flares. 7 Most topical treatments for atopic dermatitis are ...

SM17 Competitive Advantages: -First AD biologic with dual efficacy --- first and the only AD biologic that could reach both NRS-41 and EASI-752 responder rate over 60%3 simultaneously at end of ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Some topical cannabinoid therapies could be a safe and effective treatment for patients with atopic dermatitis (AD) says a recent study. According to the USA’s National Eczema Foundation, an estimated ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission. Raj Chovatiya ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

Its lead product candidate, Zabalafin Hydrogel, is being developed as a topical treatment for atopic dermatitis (AD), the most common form of eczema. Zabalafin Hydrogel has demonstrated strong ...